Gotowe bibliografie tematyczne / Neratinib

Spis treści

Artykuły w czasopismach
Rozprawy doktorskie
Streszczenia konferencji

Gotowa bibliografia na temat „Neratinib”

Autor: Grafiati

Data publikacji: 3 czerwca 2025

Data aktualizacji: 31 lipca 2025

Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych

Wybierz rodzaj źródła:

Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Neratinib”.

Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.

Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.

Artykuły w czasopismach na temat "Neratinib"

Rattanaburee, Thidarath, Tanotnon Tanawattanasuntorn, Tienthong Thongpanchang, Varomyalin Tipmanee, and Potchanapond Graidist. "Trans-(−)-Kusunokinin: A Potential Anticancer Lignan Compound against HER2 in Breast Cancer Cell Lines?" Molecules 26, no. 15 (2021): 4537. http://dx.doi.org/10.3390/molecules26154537.

Pełny tekst źródła

Streszczenie:

Trans-(−)-kusunokinin, an anticancer compound, binds CSF1R with low affinity in breast cancer cells. Therefore, finding an additional possible target of trans-(−)-kusunokinin remains of importance for further development. Here, a computational study was completed followed by indirect proof of specific target proteins using small interfering RNA (siRNA). Ten proteins in breast cancer were selected for molecular docking and molecular dynamics simulation. A preferred active form in racemic trans-(±)-kusunokinin was trans-(−)-kusunokinin, which had stronger binding energy on HER2 trans-(+)-kusunok

Style APA, Harvard, Vancouver, ISO itp.

Ito, Y., K. Hatake, S. Takahashi, et al. "Tolerability and safety of oral neratinib (HKI-272) in Japanese patients with advanced solid tumors." Journal of Clinical Oncology 27, no. 15_suppl (2009): e14505-e14505. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.e14505.

Pełny tekst źródła

Streszczenie:

e14505 Background: Neratinib (HKI-272) is a potent irreversible pan-ErbB tyrosine kinase inhibitor. In non-Japanese pts, neratinib was found to have clinical activity against solid tumors and dose-limiting toxicity (DLT) of diarrhea. The maximum tolerated dose (MTD) was 320 mg daily and the recommended dose (RD) was 240 mg because of the diarrhea. In this phase 1 study, the MTD was determined and safety and preliminary efficacy were assessed in Japanese pts with advanced solid tumors. Methods: Pts (3- 6/cohort) received 80, 160, 240, or 320 mg oral neratinib. Each pt participated in only 1 dos

Style APA, Harvard, Vancouver, ISO itp.

Klein, R. L., and J. E. Lang. "Neratinib." Drugs of the Future 35, no. 8 (2010): 621. http://dx.doi.org/10.1358/dof.2010.035.08.1514126.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Klein, R. L., and J. E. Lang. "Neratinib." Drugs of the Future 35, no. 8 (2010): 621. http://dx.doi.org/10.1358/dof.2010.35.8.1514126.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Tao, Gabriel, Fatima Dagher, and Romi Ghose. "Neratinib causes non-recoverable gut injury and reduces intestinal cytochrome P450 3A enzyme in mice." Toxicology Research 11, no. 1 (2022): 184–94. http://dx.doi.org/10.1093/toxres/tfab111.

Pełny tekst źródła

Streszczenie:

Abstract Neratinib is a pan-HER tyrosine kinase inhibitor newly approved by FDA in 2017 to treat HER2-positive breast cancer, but the phase III trial of neratinib showed that 96% of the patients taking neratinib experienced diarrhea. So far very few mechanistic studies explore neratinib-induced gastrointestinal (GI) toxicity. Hereby, we performed toxicity studies in mice to characterize the potential mechanism underlying this adverse effect. C57BL/6 J mice were separated into three groups A, B, C. Group A received vehicle; group B was orally dosed with 100 mg/kg neratinib once daily for 18 day

Style APA, Harvard, Vancouver, ISO itp.

Lee, Jangsoon, Huey Liu, Troy Pearson, et al. "PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening." Biomedicines 9, no. 7 (2021): 740. http://dx.doi.org/10.3390/biomedicines9070740.

Pełny tekst źródła

Streszczenie:

Human epidermal growth factor receptor (EGFR) 2 (HER2) is overexpressed/amplified in about 25% of all breast cancers, and EGFR is overexpressed in up to 76% and amplified in up to 24% of triple-negative breast cancers (TNBC). Here, we aimed to identify inhibitors that may enhance the anti-tumor activity of neratinib for HER2+ breast cancer and TNBC. By conducting a non-biased high-throughput RNA interference screening, we identified PI3K/AKT/mTOR and MAPK as two potential inhibitory synergistic canonical pathways. We confirmed that everolimus (mTOR inhibitor) and trametinib (MEK inhibitor) enh

Style APA, Harvard, Vancouver, ISO itp.

Arrillaga-Romany, Isabel, Lorenzo Trippa, Geffrey Fell, et al. "CTNI-05. PRELIMINARY RESULTS OF THE NERATINIB ARM IN THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT): A PHASE II PLATFORM TRIAL USING BAYESIAN ADAPTIVE RANDOMIZATION." Neuro-Oncology 23, Supplement_6 (2021): vi59. http://dx.doi.org/10.1093/neuonc/noab196.230.

Pełny tekst źródła

Streszczenie:

Abstract BACKGROUND EGFR is amplified in over 50% of glioblastoma and 20-30% have EGFRvIII mutations. Neratinib is a potent inhibitor of EGFR/HER2 approved for metastatic HER2+ breast cancer. To efficiently evaluate the potential impact of neratinib on overall survival (OS) in newly-diagnosed glioblastoma and to simultaneously develop information regarding potential genomic biomarker associations, neratinib was included as an arm on the Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) trial. INSIGhT is a phase II platform trial using response adaptive randomization a

Style APA, Harvard, Vancouver, ISO itp.

Moftakhar, Bahar, Prakash Kharel, Sujan Niraula, Shipra Gandhi, Carla Falkson, and Ajay Dhakal. "Neratinib-Induced Duodenal Ulcer: A Case Report." Breast Cancer: Basic and Clinical Research 14 (January 2020): 117822342093587. http://dx.doi.org/10.1177/1178223420935871.

Pełny tekst źródła

Streszczenie:

We report a case of a 37-year-old woman who developed a duodenal ulcer while receiving adjuvant neratinib for HER2 positive breast cancer. The clinical course of abdominal pain was strongly correlated with the use of neratinib. An esophagogastroduodenoscopy (EGD) was performed and confirmed the diagnosis of a large duodenal ulcer. Neratinib was stopped, and the patient was treated with a proton pump inhibitor. Repeat EGD performed 3 months later showed complete resolution of the duodenal ulcer. Given this unexpected serious adverse event and only modest benefit of neratinib in the adjuvant set

Style APA, Harvard, Vancouver, ISO itp.

Zhou, Guangya, Manman Zhao, Ruirui Liang, et al. "A Study of the Mechanism of Binding between Neratinib and MAD2L1 Based on Molecular Simulation and Multi-spectroscopy Methods." Current Pharmaceutical Design 25, no. 40 (2020): 4287–95. http://dx.doi.org/10.2174/1381612825666191107102413.

Pełny tekst źródła

Streszczenie:

Background: Nilatinib is an irreversible tyrosine kinase inhibitor, which is used in the treatment of some kinds of cancer. To study the interaction between Neratinib and MAD2L1, a potential tumor target, is of guiding significance for enriching the medicinal value of Neratinib. Method: The binding mechanism between Mitotic arrest deficient 2-like protein 1 (MAD2L1) and Neratinib under simulative physiological conditions was investigated by molecule simulation and multi-spectroscopy approaches. Results: Molecular docking showed the most possible binding mode of Neratinib-MAD2L1 and the potenti

Style APA, Harvard, Vancouver, ISO itp.

Moy, Beverly, Masato Takahashi, Shoichiro Ohtani, et al. "Association between treatment duration and overall survival in early-stage HER2+ breast cancer patients receiving extended adjuvant therapy with neratinib in the ExteNET trial." Journal of Clinical Oncology 39, no. 15_suppl (2021): 540. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.540.

Pełny tekst źródła

Streszczenie:

540 Background: Completion of planned treatment has been shown to improve clinical outcomes. In the ExteNET trial (NCT00878709), where diarrhea prophylaxis was not mandated, 17% of patients (pts) discontinued neratinib early due to diarrhea. This compares with 3.3% of pts from the CONTROL trial (NCT02400476) who used a neratinib dose-escalation strategy. Prior analyses have shown improved invasive disease-free survival (iDFS) in pts who completed planned duration of neratinib therapy in ExteNET (Table). Here we assess outcomes, including overall survival (OS), for pts who completed planned the

Style APA, Harvard, Vancouver, ISO itp.

Więcej źródeł

Rozprawy doktorskie na temat "Neratinib"

Hudáčová, Lenka. "Vliv inhibice bosutinibu, neratinibu a ibrutinibu na aktivitu vybraných reduktas z nadrodiny AKR a SDR." Master's thesis, 2019. http://www.nusl.cz/ntk/nusl-396799.

Pełny tekst źródła

Streszczenie:

Charles University Faculty of Pharmacy in Hradec Králové Department of Biochemical Sciences Candidate: Bc. Lenka Hudáčová Supervisor: Ing. Vladimír Wsól, Ph.D. Title of diploma thesis: The influence of bosutinib, neratinib and ibrutinib inhibition on the activity of selected reductases from AKR and SDR superfamilies Anthracycline antibiotics (ANTs) are antineoplastic drugs. Daunorubicin (DAUN) is used in the treatment of acute leukaemia. Enzymes from aldo-keto reductase (AKR) and short-chain dehydrogenase/reductase (SDR) superfamilies mediate the reduction of DAUN to its C-13 alcohol metabolit

Style APA, Harvard, Vancouver, ISO itp.

Büchner, Ingmar Christoff. "Latent potential : a post-industrial artefact : re[ge]nerating resources from a depleted quarry : architecture as interface of exchange between people and resources." Diss., 2013. http://hdl.handle.net/2263/32801.

Pełny tekst źródła

Streszczenie:

The continuing industrialisation of global society, specifically in developing countries, has resulted in the ongoing extraction of the earth's resources to feed the ever increasing demand for economic growth. What will happen when resources become scarce and unobtainable? What will happen when population growth becomes unmanageable? What will happen when the quality of life becomes displaced by the quantity thereof? The effects of such exploitation are already evident, and the longer solutions toward growing global populations and diminishing natural resources are postponed, the bleaker the f

Style APA, Harvard, Vancouver, ISO itp.

Streszczenia konferencji na temat "Neratinib"

Zhao, Ming, Stephen Scott, Kurt Evans, et al. "Abstract B003: Combinatorial therapies of neratinib for HER2-amplified cancer." In Abstracts: AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; October 26-30, 2019; Boston, MA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1535-7163.targ-19-b003.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Ogoshi, Yusuke, shinichi Toyooka, Jyunichi Soh, et al. "Abstract 4777: Antitumor effect of neratinib in lung cancers harboringHER2oncogene alterations." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-4777.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Li, Shuai, Shengwu Liu, Ting Chen, et al. "Abstract 4778: Assessing efficacy of neratinib in HER2-driven lung cancer." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-4778.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Conlon, Neil T., Jeffrey J. Kooijman, Guido JR Zaman, et al. "Abstract A046: Pre-clinical assessment of neratinib sensitivity and biomarkers of response." In Abstracts: AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; October 26-30, 2019; Boston, MA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1535-7163.targ-19-a046.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Conlon, Neil, Michelle Lowry, Susan Breslin, et al. "Abstract 1834: Src inhibition overcomes neratinib resistance in HER2-positive breast cancer." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-1834.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Bennett, Ruth, Merel Gijsen, and Anthony Kong. "Abstract 1737: Overcoming trastuzumab resistance with the irreversible Pan-HER inhibitor neratinib." In Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-1737.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Hanrahan, Aphrothiti J., David M. Hyman, John Sfakianos, et al. "Abstract 1101: Functional genomics of HER2 and HER3 mutations and response to neratinib." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-1101.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Kuraguchi, Mari, Luke J. Taus, Shan Zhou, et al. "Abstract 4806: Exploring optimal targeted combination therapies with neratinib for HER2 mutated NSCLC." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-4806.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Dart, Dafydd A., Alshad S. Lalani, Francesca Avogadri-Connors, Richard Bryce, and Wen G. Jiang. "Abstract 5468: Neratinib significantly inhibits responses to androgen in human prostate cancer cells." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-5468.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Guy, Michael K., Andre Teixeira, Alshad S. Lalani, et al. "Abstract 580: Effects of oral crofelemer on neratinib-induced diarrhea in beagle dogs." In Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-580.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Oferujemy zniżki na wszystkie plany premium dla autorów, których prace zostały uwzględnione w tematycznych zestawieniach literatury. Skontaktuj się z nami, aby uzyskać unikalny kod promocyjny!